A K Wittkowsky

Summary

Affiliation: University of Washington
Country: USA

Publications

  1. ncbi Frequency and causes of overanticoagulation and underanticoagulation in patients treated with warfarin
    Ann K Wittkowsky
    School of Pharmacy, University of Washington, Seattle, Washington, USA
    Pharmacotherapy 24:1311-6. 2004
  2. ncbi Frequency of concurrent use of warfarin with potentially interacting drugs
    Ann K Wittkowsky
    School of Pharmacy, University of Washington, Seattle, Washington, USA
    Pharmacotherapy 24:1668-74. 2004
  3. ncbi The role of oral direct thrombin inhibitors in atrial fibrillation
    Ann K Wittkowsky
    School of Pharmacy, University of Washington, Seattle, Washington 98195, USA
    Pharmacotherapy 24:190S-198S. 2004
  4. ncbi Barriers to patient self-testing of prothrombin time: national survey of anticoagulation practitioners
    Ann K Wittkowsky
    School of Pharmacy, University of Washington, Seattle, Washington, USA
    Pharmacotherapy 25:265-9. 2005
  5. ncbi Compression stockings to prevent post-thrombotic syndrome: a role for anticoagulation clinics?
    Ann K Wittkowsky
    University of Washington School of Pharmacy, Seattle, WA, USA
    J Thromb Thrombolysis 26:248-50. 2008
  6. ncbi Dietary supplements, herbs and oral anticoagulants: the nature of the evidence
    Ann K Wittkowsky
    University of Washington School of Pharmacy, Seattle, WA 98195, USA
    J Thromb Thrombolysis 25:72-7. 2008
  7. ncbi Pharmacogenomics and the management of oral anticoagulation
    Ann K Wittkowsky
    University of Washington Medical Center, 1959 NE Pacific Street, Room BB112, Box 356015, Seattle, WA 98195, USA
    Curr Hematol Rep 3:363-7. 2004
  8. ncbi Warfarin and other coumarin derivatives: pharmacokinetics, pharmacodynamics, and drug interactions
    Ann K Wittkowsky
    University of Washington School of Pharmacy Anticoagulation Services, University of Washington Medical Center, Seattle WA, USA
    Semin Vasc Med 3:221-30. 2003
  9. ncbi Effect of age on international normalized ratio at the time of major bleeding in patients treated with warfarin
    Ann K Wittkowsky
    School of Pharmacy, University of Washington, Seattle, Washington 98195, USA
    Pharmacotherapy 24:600-5. 2004
  10. ncbi New oral anticoagulants: a practical guide for clinicians
    Ann K Wittkowsky
    University of Washington School of Pharmacy, Seattle, WA, USA
    J Thromb Thrombolysis 29:182-91. 2010

Detail Information

Publications41

  1. ncbi Frequency and causes of overanticoagulation and underanticoagulation in patients treated with warfarin
    Ann K Wittkowsky
    School of Pharmacy, University of Washington, Seattle, Washington, USA
    Pharmacotherapy 24:1311-6. 2004
    ..To determine the frequency and the specific causes of over- and underanticoagulation in patients who receive warfarin therapy and are managed in an anticoagulation clinic...
  2. ncbi Frequency of concurrent use of warfarin with potentially interacting drugs
    Ann K Wittkowsky
    School of Pharmacy, University of Washington, Seattle, Washington, USA
    Pharmacotherapy 24:1668-74. 2004
    ....
  3. ncbi The role of oral direct thrombin inhibitors in atrial fibrillation
    Ann K Wittkowsky
    School of Pharmacy, University of Washington, Seattle, Washington 98195, USA
    Pharmacotherapy 24:190S-198S. 2004
    ..Ximelagatran has been investigated in patients with atrial fibrillation and has been as effective as warfarin for stroke prevention...
  4. ncbi Barriers to patient self-testing of prothrombin time: national survey of anticoagulation practitioners
    Ann K Wittkowsky
    School of Pharmacy, University of Washington, Seattle, Washington, USA
    Pharmacotherapy 25:265-9. 2005
    ..7%). Over 75% of respondents believed that some reimbursement for the cost of self-testing devices and supplies would increase the likelihood that anticoagulation clinics would recommend INR self-testing...
  5. ncbi Compression stockings to prevent post-thrombotic syndrome: a role for anticoagulation clinics?
    Ann K Wittkowsky
    University of Washington School of Pharmacy, Seattle, WA, USA
    J Thromb Thrombolysis 26:248-50. 2008
    ..By doing so, the extent of use of compression stockings might be increased, and adherence to current guidelines for strength and duration of compression might be improved...
  6. ncbi Dietary supplements, herbs and oral anticoagulants: the nature of the evidence
    Ann K Wittkowsky
    University of Washington School of Pharmacy, Seattle, WA 98195, USA
    J Thromb Thrombolysis 25:72-7. 2008
    ....
  7. ncbi Pharmacogenomics and the management of oral anticoagulation
    Ann K Wittkowsky
    University of Washington Medical Center, 1959 NE Pacific Street, Room BB112, Box 356015, Seattle, WA 98195, USA
    Curr Hematol Rep 3:363-7. 2004
    ..Routine pharmacogenomic screening has not yet been applied to clinical practice or analyzed for cost effectiveness but may be useful in identifying patients at risk for warfarin-related complications...
  8. ncbi Warfarin and other coumarin derivatives: pharmacokinetics, pharmacodynamics, and drug interactions
    Ann K Wittkowsky
    University of Washington School of Pharmacy Anticoagulation Services, University of Washington Medical Center, Seattle WA, USA
    Semin Vasc Med 3:221-30. 2003
    ..Numerous drug compounds are reported to interact with warfarin, necessitating increased prothrombin time monitoring and warfarin dosing adjustments to maintain safe and effective anticoagulation...
  9. ncbi Effect of age on international normalized ratio at the time of major bleeding in patients treated with warfarin
    Ann K Wittkowsky
    School of Pharmacy, University of Washington, Seattle, Washington 98195, USA
    Pharmacotherapy 24:600-5. 2004
    ....
  10. ncbi New oral anticoagulants: a practical guide for clinicians
    Ann K Wittkowsky
    University of Washington School of Pharmacy, Seattle, WA, USA
    J Thromb Thrombolysis 29:182-91. 2010
    ....
  11. ncbi A systematic review and inventory of supplement effects on warfarin and other anticoagulants
    Ann K Wittkowsky
    University of Washington School of Pharmacy, Anticoagulation Services, University of Washington Medical Center, 1959 NE Pacific St, P. O. Box 356015, Seattle WA 98195, USA
    Thromb Res 117:81-6; discussion 113-5. 2005
  12. ncbi The role of thrombin inhibition during percutaneous coronary intervention
    Ann K Wittkowsky
    Department of Pharmacy, University of Washington Medical Center, Seattle 98195, USA
    Pharmacotherapy 22:97S-104S. 2002
    ..Bivalirudin, a direct thrombin inhibitor, offers significant improvement over heparin in the clinical outcomes and risks associated with PCI...
  13. ncbi Warfarin-related outcomes in patients with antiphospholipid antibody syndrome managed in an anticoagulation clinic
    Ann K Wittkowsky
    University of Washington, School of Pharmacy, Seattle, WA 98195, USA
    Thromb Haemost 96:137-41. 2006
    ....
  14. ncbi Drug interactions update: drugs, herbs, and oral anticoagulation
    A K Wittkowsky
    Anticoagulation Services, Department of Pharmacy, University of Washington Medical Center, Seattle, 98195, USA
    J Thromb Thrombolysis 12:67-71. 2001
    ..Published case reports of interactions between warfarin and even the most widely used herbal medicinals are limited. Practitioners are encouraged to report such interactions through the FDA MedWatch program...
  15. ncbi Novel oral anticoagulants and their role in clinical practice
    Ann K Wittkowsky
    Department of Pharmacy, University of Washington School of Pharmacy, Seattle, Washington, USA
    Pharmacotherapy 31:1175-91. 2011
    ..These new agents represent a new paradigm for anticoagulation that promises to improve patient care in the long term...
  16. ncbi Bivalirudin: a direct thrombin inhibitor for percutaneous transluminal coronary angioplasty
    Barbara S Wiggins
    Department of Pharmacy, University of Virginia Health System, Charlottesville 22908-0674, USA
    Pharmacotherapy 22:1007-18. 2002
    ..This agent offers promise as a replacement for unfractionated heparin in PCI and is being studied in comparison with unfractionated heparin plus GP IIb-IIIa receptor inhibitors in patients undergoing intracoronary stent placement...
  17. ncbi Effective anticoagulation therapy: defining the gap between clinical studies and clinical practice
    Ann K Wittkowsky
    University of Washington School of Pharmacy, Seattle, USA
    Am J Manag Care 10:S297-306; discussion S312-7. 2004
    ..The economic implications of such a gap and strategies for closing the gap are also discussed by the panelists...
  18. ncbi An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients
    Lisa M Meckley
    University of Washington, Department of Pharmacy, Seattle, WA 98195, USA
    Thromb Haemost 100:229-39. 2008
    ..This difference may be due, in part, to pharmacokinetics factors (e.g. drug half-life), which are influenced primarily by CYP2C9; these findings should be confirmed in additional studies...
  19. ncbi Outcomes of oral anticoagulant therapy managed by telephone vs in-office visits in an anticoagulation clinic setting
    Ann K Wittkowsky
    School of Pharmacy, University of Washington, Seattle, WA, USA
    Chest 130:1385-9. 2006
    ..Telephone follow-up can be successfully used to manage warfarin therapy in patients who are unable to present in person to an anticoagulation clinic...
  20. ncbi Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy
    Mitchell K Higashi
    University of Washington, Department of Pharmacy, Box 357630, Health Sciences Bldg, Room H 375A, Seattle, WA 98195, USA
    JAMA 287:1690-8. 2002
    ..Patients with these genetic variants have been shown to require lower maintenance doses of warfarin, but a direct association between CYP2C9 genotype and anticoagulation status or bleeding risk has not been established...
  21. ncbi Adherence to guidelines for the management of excessive warfarin anticoagulation
    Emily B Devine
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Box 357630, Seattle, WA 98195 7630, USA
    J Thromb Thrombolysis 27:379-84. 2009
    ..This multi-site prospective cohort study evaluated patient-level practice patterns and adherence to ACCP guidelines...
  22. ncbi Thromboembolic complications of malignancy. Part 2: management
    Michael L Linenberger
    Division of Hematology, Department of Medicine, University of Washington, Seattle, Washington, USA
    Oncology (Williston Park) 19:1077-84; discussion 1084, 1087-8. 2005
    ..Ongoing studies are characterizing the cost-effectiveness and antitumor mechanisms of LMWHs, the potential utility of newer anticoagulants, and the ability of predictive models to identify high-risk candidates for thromboprophylaxis...
  23. ncbi Warfarin-amiodarone drug-drug interactions: determination of [I](u)/K(I,u) for amiodarone and its plasma metabolites
    M G McDonald
    Department of Medicinal Chemistry, University of Washington, Seattle, Washington, USA
    Clin Pharmacol Ther 91:709-17. 2012
    ..From these ratios, we predict that a minor metabolite of amiodarone, namely, N,N-didesethylamiodarone (DDEA), is a major contributor to the interaction between warfarin and amiodarone...
  24. ncbi Clinical use of new antithrombotic therapies for medical management of acute coronary syndromes
    B S Wiggins
    Department of Pharmacy, University of Washington Medical Center, Seattle 98195-6015, USA
    Pharmacotherapy 21:320-37. 2001
    ..Glycoprotein IIb-IIIa receptor inhibitors, low-molecular-weight heparins, and direct thrombin inhibitors have been studied as concurrent therapy with, or as alternatives to, heparin...
  25. ncbi Discrepancies in identification of major bleeding events in patients taking warfarin
    Anna C Seto
    University of Washington School of Pharmacy, Seattle, Washington 98195, USA
    Pharmacotherapy 28:1098-103. 2008
    ....
  26. ncbi Argatroban for prevention and treatment of thromboembolism in heparin-induced thrombocytopenia
    L M Kondo
    School of Pharmacy, University of Washington, Seattle, USA
    Ann Pharmacother 35:440-51. 2001
    ..Argatroban offers several practical advantages over other available agents with respect to dosing, monitoring, reversibility of effect with discontinuation of the drug, and cost...
  27. ncbi Thromboembolic complications of malignancy. Part 1: Risks
    Michael L Linenberger
    Division of Hematology and Department of Medicine, University of Washington, Seattle, USA
    Oncology (Williston Park) 19:853-61. 2005
    ..Part 2, which will appear in next month's issue, covers prophylaxis and treatment of these thromboembolic complications...
  28. ncbi Impact of oral direct thrombin inhibitors on anticoagulation clinics
    Edith A Nutescu
    Department of Pharmacy Practice, University of Illinois at Chicago, IL 60612, USA
    Pharmacotherapy 24:1204-12. 2004
    ..Clinics that are proactive and redesign their patient care services to consider emerging anticoagulant agents will be more likely to remain relevant and viable...
  29. ncbi The "pill-in-the-pocket" approach to atrial fibrillation
    Ann K Wittkowsky
    N Engl J Med 352:1150-1; author reply 1150-1. 2005
  30. ncbi Genetic testing for warfarin dosing? Not yet ready for prime time
    Henry I Bussey
    Pharmacotherapy 28:141-3. 2008
  31. ncbi Factors associated with INR elevation and bleeding complications during Warfarin therapy
    Ann K Wittkowsky
    Arch Intern Med 165:703. 2005
  32. ncbi Direct thrombin inhibitors for anticoagulation
    Edith A Nutescu
    Antithrombosis Service, College of Pharmacy, The University of Illinois at Chicago, Chicago, IL 60612, USA
    Ann Pharmacother 38:99-109. 2004
    ..To review the progress in developing direct thrombin inhibitors (DTIs) for anticoagulation within the context of existing anticoagulation therapies...
  33. ncbi Anticoagulation monitoring part 1: warfarin and parenteral direct thrombin inhibitors
    Sarah A Spinler
    Cardiovascular Division, Department of Medicine, Philadelphia College of Pharmacy, University of Pennsylvania, Philadelphia, PA 19104 4495, USA
    Ann Pharmacother 39:1049-55. 2005
    ..To review the availability, mechanisms, limitations, and clinical application of point-of-care (POC) devices used in the management of warfarin and parenteral direct thrombin inhibitors...
  34. ncbi Why warfarin and heparin need to overlap when treating acute venous thromboembolism
    Ann K Wittkowsky
    Dis Mon 51:112-5. 2005
  35. ncbi Treatment of venous thromboembolism: adherence to guidelines and impact of physician knowledge, attitudes, and beliefs
    Joseph A Caprini
    Evanston Northwestern Healthcare and Feinberg School of Medicine, Northwestern University, Chicago, Ill, USA
    J Vasc Surg 42:726-33. 2005
    ..To assess the treatment of venous thromboembolism (VTE) in hospitalized patients enrolled in a national, multicenter database...
  36. ncbi Anticoagulation monitoring part 2: Unfractionated heparin and low-molecular-weight heparin
    Sarah A Spinler
    Cardiovascular Division, Department of Medicine, Philadelphia College of Pharmacy, University of Pennsylvania, Philadelphia, PA, USA
    Ann Pharmacother 39:1275-85. 2005
    ..To review the availability, mechanisms, limitations, and clinical application of point-of-care (POC) devices used in monitoring anticoagulation with unfractionated heparin (UFH) and low-molecular-weight heparins (LMWHs)...
  37. ncbi Antithrombotic therapy practices in US hospitals in an era of practice guidelines
    Victor F Tapson
    Division of Pulmonary Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Arch Intern Med 165:1458-64. 2005
    ..Antithrombotic therapy is efficacious for the prevention of thromboembolic disease, but it necessitates careful risk-benefit assessment...
  38. ncbi Uncertain times for oral anticoagulation therapy
    Edith A Nutescu
    Am J Health Syst Pharm 62:1449. 2005
  39. ncbi Survey of pharmacist-managed inpatient anticoagulation services
    Katherine W Phillips
    Boston Medical Center, 88 East Newton Street, H2606, Boston, MA 02118, USA
    Am J Health Syst Pharm 64:2275-8. 2007
    ..The scope of existing pharmacist-managed inpatient anticoagulation services and the roles and responsibilities of the pharmacists involved were studied...
  40. ncbi Choosing the appropriate antithrombotic agent for the prevention and treatment of VTE: a case-based approach
    Edith A Nutescu
    Antithrombosis Center, Department of Pharmacy Practice, College of Pharmacy, The University of Illinois at Chicago, Chicago, IL 60612 7230, USA
    Ann Pharmacother 40:1558-71. 2006
    ..To review the risk of venous thromboembolism (VTE) in various patient populations and evaluate the agents available for the prevention and treatment of VTE using a case-based approach...
  41. ncbi Delivery of optimized anticoagulant therapy: consensus statement from the Anticoagulation Forum
    David A Garcia
    University of New Mexico School of Medicine, Albuquerque, NM, USA
    Ann Pharmacother 42:979-88. 2008
    ....